Previous 10 | Next 10 |
With the U.S. FDA saying that COVID-19 booster vaccines need to include protection against Omicron variant subvariants , Ocugen ( NASDAQ: OCGN ) could see its fortunes improved. In January, Ocugen and partner Bharat Biotech reported data on a booster dose of its Covaxi...
Ocugen (NASDAQ:OCGN) said interim data from phase 2/3 trial of Covaxin, developed by India's Bharat Biotech, was published in a journal and showed that the COVID-19 vaccine showed efficacy and superior response in children that what was seen in adults. Data from the study, which included...
Ocugen’s partner Bharat Biotech’s Phase 2/3 study of COVAXIN™ (BBV152) in 526 children showed safety, efficacy, and superior response to that shown in adults Ocugen has North American commercialization rights for COVAXIN™ MALVERN, Pa., June ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips At a time when most stocks are falling and very few are rallying, one way investors can make money is by shorting stocks . Even though the market — amid fears of continued high inflation, rising interest rates and s...
MALVERN, Pa., June 14, 2022 (GLOBE NEWSWIRE) -- Ocugen , Inc . (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal ...
MALVERN, Pa., June 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that on June 7, 2022, the United State...
Coronavirus stock Ocugen (NASDAQ: OCGN) didn't end the week on a high note. Shares of the biotech took a more than 4% tumble on Friday on the back of financing news that didn't please investors. Ocugen divulged in a pair of regulatory filings that it will sell up to $160 million...
A newly published study indicates that Covaxin, a coronavirus shot the U.S. biotech Ocugen (NASDAQ:OCGN) and India’s Bharat Biotech plan to introduce in North America, generated strong six-month-long immune memory to the COVID-19 virus and its variants. The study published in the journ...
MALVERN, Pa., June 09, 2022 (GLOBE NEWSWIRE) -- Ocugen , Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that Michael Shine, Ocugen’s Senior Vice President, C...
FTSE Russell has released a preliminary lists of companies set to join or leave the Russell Microcap Index as part of its 2022 annual reconstitution. Notable health care additions include: Inovio Pharma (INO), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), Ocu...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to ...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...